Article
Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Jul 2014
Karlan Beth Y, Thorpe Jason, Watabayashi Kate, Drescher Charles W, Palomares Melanie, Daly Mary B, Paley Pam, Hillard Paula, Andersen M Robyn, Anderson Garnet, Drapkin Ronny, Urban Nicole
Abstract excerpt
BACKGROUND: Serum markers are used before pelvic imaging to improve specificity and positive predictive value (PPV) of ovarian cancer multimodal screening strategies. METHODS: We conducted a randomized controlled pilot trial to estimate surgical PPV of a "2 of 3 tests positive" screening rule, and to compare use of HE4 as a first-line (Arm 1) versus a second-line (Arm 2) screen, in women at high and elevated risk...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.